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Abstract
Rationale, aims and objectives In the UK fewer than 15% of familial
hypercholesterolemia (FH) cases are diagnosed, representing a major gap in coronary heart
disease prevention. We wished to support primary care doctors within the Medway Clinical
Commissioning Group (CCG) to implement NICE guidance (CG71) and consider the
possibility of FH in adults who have raised total cholesterol concentrations, thereby
improving the detection of people with FH.
Methods Utilizing clinical decision support software (Audit+) we developed an FH Audit
Tool and implemented a systematic audit of electronic medical records within GP prac-
tices, first identifying all patients diagnosed with FH or possible FH and next electronically
flagging patients with a recorded total cholesterol of >7.5 mmol L−1 or LDL-
C > 4.9 mmol L−1 (in adults), for further assessment. After a 2-year period, a nurse-led
clinic was introduced to screen more intensely for new FH index cases. We evaluated if
these interventions increased the prevalence of FH closer to the expected prevalence from
epidemiological studies.
Results The baseline prevalence of FH within Medway CCG was 0.13% (1 in 750
persons). After 2 years, the recorded prevalence of diagnosed FH increased by 0.09% to
0.22% (1 in 450 persons). The nurse advisor programme ran for 9 months (October
2013–July 2014) and during this time, the recorded prevalence of patients diagnosed with
FH increased to 0.28% (1 in 357 persons) and the prevalence of patients ‘at risk and
unscreened’ reduced from 0.58% to 0.14%.
Conclusions Our study shows that two simple interventions increased the detection of FH.
This systematic yet simple electronic case-finding programme with nurse-led review
allowed the identification of new index cases, more than doubling the recorded prevalence
of detected disease to 1 in 357 (0.28%). This study shows that primary care has an
important role in identifying patients with this condition.
Introduction
Familial hypercholesterolaemia (FH) is an autosomal co-
dominant lipid disorder that confers an increased risk of prema-
ture coronary heart disease (CHD) because of lifelong exposure
to high concentrations of low-density lipoprotein-cholesterol
(LDL-C) [1]. Untreated, FH-associated elevated LDL-C results
in a greater than 50% risk of CHD in men by the age of 50 years
and of at least 30% in women by the age of 60 years [2]. FH is
an important, under-diagnosed cause of premature CHD.
National Institute for Health and Care Excellence (NICE)
Quality Standard guidance (QS41) [3], European Atherosclerosis
Society (EAS) consensus statement [4] and guidance from the
International FH Foundation [5] recognize under-diagnosis of
FH as a significant issue to be addressed. The EAS has called for
more action for FH as early identification and optimal treatment
from a young age is crucial to providing a long and healthy life
for affected children and adolescents [6]. In the UK, the Depart-
ment of Health Cardiovascular Disease Outcomes Strategy rec-
ognizes improving identification of inherited cardiac conditions,
and FH in particular, as a strategic priority requiring action
[7].
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According to NICE, the prevalence of heterozygous FH in the
UK population is estimated to be 1 in 500, which means that
approximately 110 000 people are affected [2]. However, recent
population data from Denmark show that possibly up to one in 200
people are heterozygous for FH and one in 160 000–300 000 have
homozygous FH [4,8]. This data are supported by a recent
genotyping study conducted in the USA, which demonstrated that
1 in 217 controls carried an LDLR-coding sequencing mutation
and had LDL-C > 4.9 mmol L−1 [9]. Based on these data [4,8,9], as
many as 300 000 people in the UK may have FH. However, a
recent national audit estimated that only 15 000 patients have a
formal diagnosis of FH [10]. This substantial under-diagnosis rep-
resents a major gap in CHD prevention in the UK, especially when
it is proven that reduced exposure to LDL-C early in life is asso-
ciated with a large reduction in CHD [11]. Lipid-lowering treat-
ments, such as statins, can reduce plasma LDL-C concentrations
and reduce mortality in FH patients [12,13]. Importantly, patients
with FH benefit most from early diagnosis and treatment, thus
avoiding lifelong exposure to raised LDL-C with studies showing
that diet, lifestyle and statin therapy from a young age substan-
tially delays atherosclerosis progression and reduces cardiovascu-
lar risk [6].
FH can be diagnosed using phenotypic criteria and genetic
testing. These include very high LDL-C (>4.9 mmol L−1 for
adults) on repeat measurements, family history, clinical history of
premature CHD and tendon xanthomas and corneal arcus on
physical examination. In the UK, the ‘Simon Broome Criteria’ are
recommended to evaluate patients with raised LDL-C [1,2]. In
Europe, the Dutch Lipid Clinic Network (DLCN) criteria are
widely used and provide a numerical score to predict the probabil-
ity of diagnosing FH on genetic testing [4]. This scoring system is
increasingly accepted as simple and comprehensive [5], categoriz-
ing patients as having definite, probable or possible FH [5].
Genetic testing of FH index cases is recommended and in those
cases where a pathogenic mutation is identified systematic cascade
testing of close relatives who carry a 50% risk of the disorder, is a
cost-effective approach to diagnose new cases of FH, particularly
in younger family members [14]. However, cascade testing from
known index cases will not identify all FH cases and fewer than
50% of all cases in a population may be identified by this approach
[2]. Therefore, a strategy to detect new index cases is essential to
improve diagnosis of FH and prevent CHD within a population
[15,16].
General practitioners (GPs) are well placed to lead on the iden-
tification of new index cases – the majority of LDL-C measure-
ments are requested within primary care and GPs have access to
electronic patient records that lend themselves to simple electronic
prompts and audits of patient data. The primary care approach to
FH diagnosis can be opportunistic, relying on GPs to consider the
diagnosis of FH in patients with elevated LDL-C, or systematic,
using an informatics-based approach to search electronic patient
records and identify people who fulfil the profile of FH for further
review [16,17].
In 2008, NICE issued guidance for FH (CG71) recommending
that health care professionals consider the possibility of FH in
adults with raised cholesterol, especially in those with a personal
or family history of CHD [2]. However, despite these guidelines,
and subsequent NICE quality standards (QS41) issued in 2013 [3],
substantial improvements in FH diagnosis were not being made.
NHS Medway CCG considered that increased detection of patients
with FH in primary care and the identification of additional ‘at
risk’ relatives would lead to better patient management with sig-
nificant benefit to patients and economic benefit to the CCG
through reduced preventable cardiovascular events. NHS Medway
CCG set out to support GPs to follow CG71 and introduced a
systematic informatics-based audit of electronic medical records
to improve the identification of people with FH followed by a
nurse-led clinic to screen more intensely for new FH index cases.
Methods
Setting
This study was conducted in NHS Medway CCG between October
2011 and July 2014. Medway is a CCG of 56 General Practices
serving approximately 290 000 patients. Practice sizes range from
1499 to 19 818 people. In 2011, 37 200 people were aged >65
years and 4400 aged >85 years. The ethnic profile of east Kent
shows that the population is predominantly white (93.4%, with
2.6% Asian, 1.7% black, 1.4% mixed and 1% Chinese/other). Life
expectancy in Medway is significantly worse than the average in
England. Medway is ranked within the 41% most deprived bor-
oughs nationally in The Index of Deprivation 2010 and includes an
area ranked in the most deprived 3% of areas nationally. This study
aligned with the overall vision of NHS Medway CCG – ‘from
reactive to proactive for a healthier Medway’ – and with the stra-
tegic objective of disease prevention – ‘to prevent people becom-
ing ill and to support people to live healthy and well through a
systematic approach in primary care that identifies patients at risk’.
Development of the FH Audit Tool using
electronic audit software
This study utilized Audit+ software (BMJ), a cross-platform,
primary care data analysis tool that was designed specifically for
use within consortia, CCGs and other commissioning organiza-
tions. Audit+ enables practices to manage their patient registers as
defined in an audit specification, easily identify patients who
require attention and set the software to prompt the clinician for
intervention opportunities automatically when they consult a
patient. Audit+ is used widely across NHS Medway CCG, with
around 30 audits currently running. As practices are familiar with
performing standard audits, no additional training for GPs was
required.
The FH Audit Tool was developed in accordance with the Royal
College of GPs’ standard criteria for audits and was based on the
recommendations of NICE CG71. Specifically, a diagnosis of FH
was based on the Simon Broome criteria [2], which classify the
patient as definite FH or possible FH (Table 1). As there was no
Read Code available for patients classified as ‘possible FH’, we
sought and obtained a Read Code from the NHS in 2010. The FH
Audit Tool provided prompts to consider a diagnosis of FH based
on the Simon Broome criteria (definite or possible FH). The trig-
gers and prompts within the FH Audit Tool are detailed in Table 2.
The FH Audit Tool was developed and piloted in a single practice
in September 2011 to test and optimize performance. The baseline
prevalence of FH was determined at study initiation, defined as all
patients previously assigned a Read code for FH according to
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Simon Broome criteria (Table 2). Improvements in FH diagnosis
were assessed over the 2-year time period.
The nurse-led clinics conducted in the second part of the study
employed the Simon Broome Criteria as well as the DLCN criteria
(Table 3). This alternative phenotypic scoring system for FH pro-
vides a numeric score and defines FH as definite, probable and
possible. Prior to the introduction of nurse-led clinics, a read code
for probable FH was requested and provided and the FH Audit
Tool enhanced to include the DLCN score to define the severity of
FH to further support clinical management.
Systematic assessment for FH diagnosis
The FH Audit Tool identified and flagged all patients at potential
risk of FH according to elevated cholesterol (total cholesterol level
>7.5 mmol L−1 in adults or >6.7 mmol L−1 in children <16 years or
LDL-C > 4.9 mmol L−1 in adults or >4.0 mmol L−1 in children) for
further assessment. These patients were termed ‘at risk and
unscreened’. During the course of the next 2 years, electronic
prompts appeared when the patient was in the practice that sought
to enhance the GPs’ decision making on FH diagnosis and to help
confirm or refute an FH diagnosis.
Enhanced assessment for FH with
nurse-led clinics
The nurse-led clinics, which formed an ‘FH Nurse Advisor Pro-
gramme’, began in October 2013 and ran for 9 months to study
end. The programme was conducted by one nurse employed by
Ashfield Health Care Ltd and trained by HEART UK and care was
consistent with the NICE clinical guideline 71 [2]. The nurse was
governed by the Nursing and Midwifery Council Code of Profes-
sional Conduct.
The nurse reviewed the audit list of ‘at risk and unscreened
patients’ to identify any missing clinical or non-clinical parameters
in individual patient records that prevented a calculation of a
DLCN score. Missing clinical parameters were sought from the
relevant health care professionals and missing non-clinical param-
eters, for example, incomplete family history, triggered an invita-
tion to the FH nurse advisor clinic. Once all parameters were
collated, a DLNC score was calculated. Patients with DLNC
scores ≥6, which indicated definite or probable FH, and those
patients with missing non-clinical parameters, were invited to
attend the FH nurse advisor clinic. Those patients with possible FH
(score 3–5), were referred to other health care professionals for
Table 1 The Simon Broome Register criteria (total cholesterol and LDL-C levels either pre-treatment or highest on treatment) [1,2]
Definite FH Possible FH
Total cholesterol >6.7 mmol L−1 or LDL-C > 4.0 mmol L−1 in a child aged
<16 years
or
Total cholesterol >7.5 mmol L−1 or LDL-C > 4.9 mmol L−1 in an adult
Total cholesterol >6.7 mmol L−1 or LDL-C > 4.0 mmol L−1 in a child aged
<16 years
or
Total cholesterol >7.5 mmol L−1 or LDL-C > 4.9 mmol L−1 in an adult
Plus And at least one of the following
Tendon xanthomas in the patient or a first-degree (parent, sibling or
child) or second-degree relative (grandparent, uncle or aunt)
or
DNA-based evidence of an LDLR mutation, familial defective
APOB-100 or a PCSK9 mutation
A family history of myocardial infarction: <50 years of age in
second-degree relative or <60 years of age in first-degree relative
or
A family history of raised total cholesterol: > 7.5 mmol L−1 in an adult
first-degree or second-degree relative or >6.7 mmol L−1 in a child or
sibling aged <16 years
Table 2 Triggers and prompts provided by FH Audit Tool
Trigger Prompt
Patients with FH or possible FH whose family has not been
informed
Have relatives been informed regarding FH?
Patients with FH, possible FH or probable FH whose latest total
cholesterol is >5 mmol L−1
Up-titrate statins or consider referral*
Patients whose latest cholesterol is >7.5 mmol L−1 or
LDL-C > 4.9 mmol L−1 and who have had a positive genotype test
Diagnose FH
Patients whose latest cholesterol is >7.5 mmol L−1 or
LDL-C > 4.9 mmol L−1 and have a family history of premature
CHD and/or hypercholesterolaemia and have not had a Simon
Broome assessment
Consider possible FH
Patients whose latest cholesterol is >7.5 mmol L−1 or
LDL-C > 4.9 mmol L−1, have not had a Simon Broome
assessment and have a family history of CHD but no details of
the age of the relatives
Ask patient if myocardial infarction has occurred before 50 years of
age in a second-degree relative or before 60 years of age in a
first-degree relative – Yes, then consider FH; No, assess using
Simon Broome criteria
*Assessment of this prompt was not undertaken as part of this audit.
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health assessment and lifestyle advice. This pathway is shown in
Fig. 1.
At the clinic, conducted at a patient’s own GP surgery, the nurse
explained the purpose of the clinic, provided a Patient Service
User Guide and an FH education leaflet and obtained written
consent. During the 30-minute appointment, clinical examination
for xanthoma or corneal arcus was conducted, and a family history
recorded as specified in Simon Broome and DLCN. Cascade
testing was discussed and if a diagnosis of FH was made, patients
were provided with cascade letters to pass on to their first-degree
relatives. The role of lifestyle factors was discussed and informa-
tion and advice were offered, aimed at improving patient concord-
ance to prescribed lipid-lowering medication and increasing the
patient’s understanding of their disease. The FH Nurse Advisors
role was limited to discussing FH, disease severity and any man-
agement issues based on clinical assessment and current NICE
guidelines. In the event of a patient not attending the clinic, the
patient was flagged to the GP practice for appropriate follow-up.
After clinic completion, the FH Nurse Advisor attended the
practice at a later date and worked with the practice to ensure the
findings of the FH review were included in the electronic clinical
records. Any medical interventions were decided by the GP. The
Nurse Advisor made recommendations to the GP based on the
clinic review – those patients diagnosed with FH were recom-
mended for referral to secondary care for specialist management;
probable or possible FH were recommended for management
within primary care, but with secondary care referral if LDL-C
levels were not controlled, if there was previous referral to sec-
ondary care of a family member, or if there was a family history of
vascular events.
Results
The majority of GP practices (53/56, 95%) in NHS Medway CCG
participated in the Audit. Three practices without Audit+-
compatible IT systems were unable to take part and accounted for
approximately 8000 patients (at study close in July 2014). Forty-
seven of 53 GP practices (89%) participated in the FH Nurse
Advisor Programme. One practice closed during the nurse advisor
programme, and the remaining five GP practices that did not
participate in the nurse programme each serviced an average 5000
patients. Despite this, no areas of the CCG were excluded, as the
areas of participating practices overlapped with non-participating
practices. The Nurse Advisor Programme reviewed the records of
1505 patients. Of 210 patients invited for clinic visits, 109 (52%)
attended.
The baseline recorded prevalence of FH within Medway CCG
was 0.13% (1 in 750 persons). The proportion of patients ‘at risk
and unscreened’ was 0.59% (Fig. 2; Table 4). After 2 years, the
recorded prevalence of diagnosed FH increased by 0.09% to
0.22% (1 in 450 persons). The proportion of patients ‘at risk and
unscreened’ was 0.58%. After the completion of the Nurse Advisor
Programme, the recorded prevalence of patients diagnosed with
FH increased to 0.28% (1 in 357 persons). This included 0.03% of
patients that were categorized as ‘probable FH’ based on the
DLCN score. The proportion of patients ‘at risk and unscreened’
was reduced to 0.14%, and this reduction is shown in Fig. 2.
In terms of patient numbers, an additional 99 cases of FH were
diagnosed during the 2-year period. During the 9 months of the
nurse advisor programme, an additional 334 cases were diagnosed
– 192 with definite FH (DLNCS >8), 83 patients with probable FH
(DLCNS 6–8) and 59 with possible FH (DLNCS 3–5). Overall, an
additional 433 index patients with FH were identified within NHS
Medway CCG (Table 4). The number of people at risk and
unscreened reduced from 1553 to 398 and this reduction is seen in
Fig. 2.
Discussion
Our study shows that two interventions increased the detection of
FH within a CCG. Using an electronic audit tool, running on GP
electronic patient record systems increased the recorded preva-
lence of diagnosed FH from one in 750 at audit initiation (0.13%)
to one in 450 (0.22%) after 2 years. Opportunistic identification of
patients with specific computer reminders had little impact on the
number of patients identified as at risk and unscreened. The two-
stage process of systematic identification with FH nurse specialist
assessment increased the proportion of patients diagnosed with FH
to one in 357 (0.28%), approaching the Danish and US estimated
FH population prevalence of approximately one in 200 [4,8,9].
Table 3 Dutch Lipid Clinic Network criteria for making a phenotypic
diagnosis of FH in adults [4]
Criteria Score
Family history
First-degree relative with known premature coronary
and/or vascular
disease (men aged <55 years, women aged <60 years)
or
First-degree relative with known LDL-C above the
95th percentile for age and gender
1
First degree relative with tendinous xanthomata
and/or arcus cornealis
or
Children aged <18 years with LDL-C above the 95th
percentile for age and gender
2
Clinical history
Patients with premature coronary artery disease (men
aged <55 years, women aged <60 years)
2
Patients with premature cerebral or peripheral
vascular disease (men aged <55 years, women
aged <60 years)
1
Physical examination
Tendinous xanthomata 6
Arcus cornealis before 45 years of age 4
Investigation
LDL-C ≥ 8.5 mmol L−1 8
LDL-C 6.5–8.4 mmol L−1 5
LDL-C 5.0–6.4 mmol L−1 3
LDL-C 4.0–4.9 mmol L−1 1
Diagnosis Total score*
Definite FH >8
Probable FH 6–8
Possible FH 3–5
Unlikely FH <3
*Total score is calculated by adding together the single highest score
from each of the four domains.
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Figure 1 Enhanced assessment for FH with nurse-
led clinics.
1 At ‘risk and unscreened’ patients identified via
FH Audit Tool, that is, total cholesterol level
>7.5 mmol L−1 in adults or >6.7 mmol L−1 in chil-
dren <16 years or LDL-C > 4.9 mmol L−1 in adults or
>4.0 mmol L−1 in children and unscreened by
Simon Broome.
2 Patients with probable and possible FH were
managed within primary care but with secondary
care referral if LDL-C levels were not controlled, if
there was a family history of specialist lipid man-
agement, or if there was a family history of vascu-
lar events.
Figure 2 Recorded prevalence of FH diagnosis and proportion of patients ‘at risk and unscreened’ over the course of the study.
October 2011–November 2013: all FH diagnoses made by Simon Broome criteria, after November 2013 FH diagnoses made by Simon Broome criteria
and/or DLCN score; patients were considered to be ‘at risk and unscreened’ if they had a total cholesterol >7.5 mmol L−1 and/or LDL-C > 4.9 mmol L−1
(adults) and had not been assessed using the Simon Broome criteria.
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The programme identified 433 new FH index cases, more than
doubling the prevalence of detected disease and allowing appro-
priate referral to secondary care for cascade testing. We suggest
the burden placed on individual practices by this increase in FH
diagnosis is manageable. For a large practice of more than 10 000
patients, approximately 60 patients would require further review.
After assessment, our prevalence figures suggest about 30 new
index cases would be identified and require referral and ongoing
management.
GP participation in this study was high. The FH Audit Tool was
incorporated in the majority of GP practices in Medway (95%) and
all practices with compatible electronic patient record systems
participated. Eighty-nine per cent of eligible practices took part in
the Nurse Advisor Programme with six eligible practices declining
to participate, but the audit tool remained in use. The full geo-
graphical area of the CCG was covered, with the practice areas of
participating practices overlapping with non-participating prac-
tices. The proportion of patients accepting the invitation to the
nurse clinic was high (52%). A further strength of the study is the
timeframe, with FH prevalence recorded over an almost 3-year
period.
An obvious limitation was the completeness of the electronic
patient records. The FH nurse sought missing data from the health
care professional or patient, but undocumented information may
have resulted in missed diagnoses. This is particularly pertinent for
family history of CHD, with patients perhaps unaware of the
extent of CHD in their family or where such information had not
been collected or recorded. This was a pragmatic clinical audit
conducted in real-world practice. As such, there was no retrospec-
tive review of patients previously coded as FH, either at baseline or
after the introduction of DLNC to confirm the previous Simon
Broome FH diagnoses. Coding in primary care is notoriously
inaccurate, and therefore, the baseline prevalence reported may not
be accurate.
Identification of FH via the FH Audit Tool relies on a record of
total cholesterol and or LDL-C values in patients’ electronic
record. Patients aged 40 years and above are more likely to have
lipid values recorded as a consequence of the NHS Health Check
programme. Younger patients, in particular children and young
adults, are unlikely to have lipid values on record. This points to
the importance of identifying new index cases, which can then
trigger cascade testing to identify younger family members who
may not be identified by an electronic audit. It is unknown what
proportion of the Medway population had lipid results available
for assessment in this study.
NICE guidance recommends genetic testing of all index cases
and cascade testing of family members as a cost-effective method
for identifying new cases of FH [2]. Genetic testing for FH is not
routinely available in England and was not included as part of this
audit. However, with the new NHS commissioning structure and
its commitment to increased investment into genetic sequencing
resources, genetic confirmation of clinically diagnosed FH cases is
certainly feasible [18,19]. When available, genetic testing will
allow mutation carriers to be distinguished from those with
polygenic FH [19] and focus resources on cascade testing in the
40% of clinically diagnosed FH patients with an identified single
gene alteration [15].
The purpose of the audit was to increase detection of FH and
suggest appropriate management of these patients based on NICE
clinical guidance [2]. However, the FH audit tool did not allow
assessment of pre- and post-diagnosis lipid levels; therefore, in the
context of this study, it is not known if diagnosis of FH led to
improved patient management and a reduction in lipid levels. A
future FH Audit Tool should address this issue and potentially
measure changes in lipid levels pre- and post-diagnosis to assess
patient management. Secondary causes of raised lipids are an
important clinical consideration. Secondary causes of raised lipids
could be assessed in patients ‘unscreened and at risk’ and invited to
the nurse clinic. Future programmes should consider a clinic visit
for all unscreened and at-risk patients to eliminate secondary
causes of dyslipidaemia.
Our study demonstrates that there is an opportunity to increase
the diagnosis of FH by exploiting the information contained within
GP electronic patient records using automated systems. While
each new diagnosis allows appropriate management and treatment
of that person, an additional benefit is that each new case acts as a
trigger for cascade testing to identify younger family members
who may not otherwise be detected and who benefit most from
Table 4 Medway FH Audit Tool results
Baseline* (October 2011) 2-year audit* (October 2013) FH Nurse Advisor Programme† (July 2014)
Population 262 030 199 346 ‡ 281 655
Number Prevalence (%) Number Prevalence (%) Number Prevalence (%)
FH 331 0.13 354 0.18 546 0.19
Probable FH NA§ NA§ NA§ NA§ 83 0.03
Possible FH 12 0.005 88 0.04 147 0.05
Total FH 343 0.13 442 0.22 776 0.28
At risk and unscreened 1553 0.59 1164 0.58 398 0.14
*FH diagnoses made by Simon Broome criteria; patients were considered to be ‘at risk and unscreened’ if they had a total cholesterol >7.5 mmol L−1
and/or LDL-C > 4.9 mmol L−1 and had not been assessed using the Simon Broome criteria.
†FH diagnoses made by Simon Broome criteria and/or DLCN score.
‡Population (and number of FH) is lower than previous time-point; data could not be extracted from all electronic medical information systems at this
time.
§FH diagnoses made by Simon Broome criteria, which does not include ‘probable FH’.
NA, not applicable.
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early diagnosis and appropriate treatment. Ultimately improving
diagnosis should lead to optimized therapeutic intervention and
hence reductions in CHD in this high-risk patient group. The next
step is to enhance the FH Audit Tool to measure the impact of
diagnosis on patient management and to provide the FH Audit Tool
widely to other interested CCGs.
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